Friedl-Naderer Johanna 4

What Happened
Johanna Friedl‑Naderer, Chief Commercial Officer of Dyne Therapeutics (DYN), reported the sale of 148 shares on 2026-03-05 at $14.90 per share, totaling $2,205. The shares were automatically sold to cover tax withholding related to the vesting of restricted stock units (RSUs) and do not represent a discretionary trade.

Key Details

• Transaction date: 2026-03-05; Sale price: $14.90 per share; Shares sold: 148; Proceeds: $2,205.
• Footnote: The sale was automatic under an RSU agreement to satisfy tax withholding obligations and is described as a "binding contract" consistent with a Rule 10b5‑1 affirmative defense (i.e., not a discretionary sale).
• Holdings noted in the filing include 129,790 unvested RSUs.
• Filing date: 2026-03-06 for a 2026-03-05 transaction — filed promptly (not marked late).

Context
Tax‑withholding sales following RSU vesting are common and typically administrative; they do not necessarily signal insider sentiment about the company's prospects. For retail investors, outright purchases are generally more informative about insider confidence than routine withholding sales.